Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
ADMA Biologics, Inc. (NASDAQ:ADMA) recently reported a series of transactions by its director, Lawrence P. Guiheen, revealing significant activity in the company’s stock. On May 21 and 22, Guiheen sold a total of 9,000 shares of ADMA common stock, generating approximately $182,635. The shares were sold at prices ranging from $20.12 to $20.32 per share, close to the current trading price of $20.42. The stock has shown remarkable strength, delivering a 113.6% return over the past year. According to InvestingPro analysis, ADMA currently appears overvalued relative to its Fair Value.
In addition to these sales, Guiheen also exercised stock options, acquiring 9,000 shares of common stock at a price of $5.96 per share. These transactions reflect Guiheen’s ongoing engagement with ADMA Biologics’ stock, as he continues to manage his holdings in the company. Following these transactions, Guiheen directly owns 114,830 shares of ADMA common stock in a company that boasts an excellent financial health score and impressive 62% revenue growth. InvestingPro subscribers can access 12 additional key insights and a comprehensive Pro Research Report about ADMA’s future prospects.
In other recent news, ADMA Biologics reported strong financial results for the first quarter of 2025, with revenue reaching $114.8 million, surpassing forecasts and marking a 40% year-over-year increase. The company’s adjusted revenue was $118.6 million, reflecting a 45% growth. ADMA Biologics’ gross profit stood at $61.1 million, with an impressive 53.2% margin, while adjusted EBITDA increased by 81% to $47.9 million. The company also reported a GAAP net income of $26.9 million and an adjusted net income of $33.3 million, an 87% year-over-year growth.
These results were bolstered by the FDA’s approval of a new production process, which is expected to enhance efficiency and output. ADMA Biologics projects a revenue of $500 million or more for 2025, with an adjusted EBITDA of at least $235 million. Looking forward to 2026, the company expects revenue to reach $625 million, with an adjusted EBITDA of $340 million or more. Additionally, the company announced a stock repurchase program of up to $500 million, reflecting confidence in its financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.